Search

Your search keyword '"Dillner, Joakim"' showing total 779 results

Search Constraints

Start Over You searched for: Author "Dillner, Joakim" Remove constraint Author: "Dillner, Joakim" Search Limiters Peer Reviewed Remove constraint Search Limiters: Peer Reviewed
779 results on '"Dillner, Joakim"'

Search Results

6. Human papillomavirus negative high grade cervical lesions and cancers: Suggested guidance for HPV testing quality assurance

9. IPVS policy statement on HPV nucleic acid testing guidance for those utilising/considering HPV as primary precancer screening: Quality assurance and quality control issues

11. Impact of cervical screening by human papillomavirus genotype: Population-based estimations

13. Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial

14. Comparing one dose of HPV vaccine in girls aged 9–14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial

17. Quadrivalent HPV (4vHPV) vaccine immunogenicity and safety in women using immunosuppressive drugs due to solid organ transplant.

18. Low methylation marker levels among human papillomavirus‐vaccinated women with cervical high‐grade squamous intraepithelial lesions.

19. Continuous Global Improvement of Human Papillomavirus (HPV) Genotyping Services: The 2022 and 2023 HPV LabNet International Proficiency Studies.

22. The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples

27. Determinants of Human Papillomavirus Vaccine Uptake by Adult Women Attending Cervical Cancer Screening in 9 European Countries

28. Nationwide registry‐based trial of risk‐stratified cervical screening.

31. Head-to-head comparison of two human papillomavirus vaccines for efficacy against cervical intraepithelial neoplasia grade 3 and adenocarcinoma in situ--population-based follow-up of two cluster-randomized trials.

32. Criteria for second generation comparator tests in validation of novel HPV DNA tests for use in cervical cancer screening.

33. Seroepidemiological assessment of the spread of SARS-CoV-2 among 25 and 28 year-old adult women in Finland between March 2020-June 2022.

34. Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries

37. Antibodies to SARS-CoV-2 and risk of past or future sick leave

38. Multianalyte serology in home-sampled blood enables an unbiased assessment of the immune response against SARS-CoV-2

40. Evaluation of 11 SARS-CoV-2 antibody tests by using samples from patients with defined IgG antibody titers

42. Scientific approaches toward improving cervical cancer elimination strategies.

43. Divergent effects of switching from cytology to HPV-based screening in the Nordic countries.

Catalog

Books, media, physical & digital resources